Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections

SCYNEXIS, Inc. (NASDAQ: SCYX) operates as a biotechnology company, which is focused on the research and development of novel solutions to treat drug-resistant and difficult-to-treat infections. Shares of the biotech company are surging 55% through early trading on Thursday, March 30, 2023. Over the past three months, SCYNEXIS has seen average daily volume of 416,600 shares. However, volume of 29.16 million shares or dollar volume of around $73.48 million, has already exchanged hands through early trading.

Shares of SCYNEXIS are soaring after the company announced it has entered into an exclusive license agreement with GSK plc (NYSE: GSK), which will focus on the commercialization of Brexafemme, a U.S. FDA-approved, first-in-class antifungal treatment for vulvovaginal candidiasis (VVC & RVVC). Under the agreement, GSK will have the right to commercialize Brexafemme for VVC and RVVC, while also continuing to develop ibrexafungerp, a Phase 3 drug candidate for the treatment of invasive candidiasis (IC), which can be a very serious fungal infection that could lead to death.

According to the exclusive agreement, GSK will pay SCYNEXIS an upfront payment of $90 million, with additional potential milestone payments totaling $503 million. Up to $245.5 million of specific milestones will be payable based on development, regulatory and commercial milestones in relation with ibrexafungerp and the treatment of IC. Another $15 million milestone will be payable to SCYNEXIS if ibrexafungerp is successfully approved by the Food and Drug Administration. The remaining $242.5 million in potential milestone payments will be tied to sales-related milestones.

David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS: “This agreement represents a major milestone for SCYNEXIS, maximising Brexafemme’s commercial potential in VVC and further validating our vision of the critical role for this first-in-class antifungal in invasive infections. We are thrilled to partner with GSK on this high-potential asset and will continue progressing ibrexafungerp’s phase III program in invasive candidiasis (IC).”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.